Bristol Myers Squibb Signs US$15.2 B Licensing Pact with Hengrui Pharma for Medicines Across Oncology, Haematology, and Immunology
By Sanya Sekhri
Pharma Deals Review: Vol 2026 Issue 5 (Table of Contents)
Published: 20 May-2026
DOI: 10.3833/pdr.v2026.i5.3017 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In one of the largest partnerships of 2026 so far, Bristol Myers Squibb (BMS) has signed a licensing agreement with Hengrui Pharma to develop a portfolio of 13 early-stage programmes in oncology, haematology, and immunology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS